Wells Fargo Upgrades Apellis Pharmaceuticals to Overweight, Raises Price Target to $64
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Derek Archila has upgraded Apellis Pharmaceuticals from Equal-Weight to Overweight and raised the price target from $34 to $64.
September 15, 2023 | 9:25 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Apellis Pharmaceuticals has been upgraded to Overweight from Equal-Weight by Wells Fargo, with a raised price target of $64.
The upgrade from Equal-Weight to Overweight by Wells Fargo indicates a positive outlook for Apellis Pharmaceuticals. The raised price target from $34 to $64 suggests that the analyst expects the stock to outperform in the short term. This could lead to increased investor interest and potentially a rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100